Establishment of the healthcare business and expansion of high-performance mask products and sales channels
First written in FY2021-Q2. 3 of 8 entries say "Advanced", first in FY2021-Q3. Latest entry: FY2023-Q3.
0 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「Beginning with the first quarter of the current consolidated fiscal year, in view of the healthcare business's impact on consolidated results, we will disclose it as part of the construction-equipment filter business. Accordingly, the reporting segments have changed from the previous three segments, "Construction-Equipment Filter Business," "Air Filter Business" and "Healthcare Business," to "Construction-Equipment Filter Business" and "Air Filter Business."」
The reporting-segment change to include the healthcare business in the construction-equipment filter business continues to be applied. - FY2023-Q1ReframedAnnual report
「Beginning with the first quarter of the current consolidated fiscal year, in view of the healthcare business's impact on consolidated results, we will disclose it as part of the construction-equipment filter business. Accordingly, the reporting segments have changed from the previous three segments, "Construction-Equipment Filter Business," "Air Filter Business" and "Healthcare Business," to "Construction-Equipment Filter Business" and "Air Filter Business."」
The reporting classification changed from disclosing the healthcare business as a standalone reporting segment to including it in the construction-equipment filter business. - FY2022AdvancedAnnual report
「In the healthcare business, the recognition of an impairment loss of ¥919 million as an extraordinary loss as part of fundamental business-structure reforms to address major changes in the business environment resulted in a substantial full-year decline in revenue and profit. In the fourth quarter, however, the company reviewed its distribution channels and restructured unprofitable products, securing operating profit.」
While reporting a full-year decline in revenue and profit in the healthcare business due to the impairment loss, the company reviewed its distribution channels and restructured unprofitable products, securing operating profit in the fourth quarter. - FY2022-Q3Business continuity has become extremely difficultAnnual report
「In the healthcare business, future demand is extremely uncertain due to major changes in the market environment and other factors, making business continuity extremely difficult. Accordingly, we recognized an impairment loss of ¥919 million on all property, plant and equipment invested in the business as an extraordinary loss. Through this action, we will rapidly implement fundamental business-structure reforms to improve profitability in the healthcare business, while urgently improving profitability across the Group.」
The company disclosed the uncertainty of demand and the difficulty of continuing the healthcare business, and recognized an impairment loss of ¥919 million on all related property, plant and equipment. It stated that this would serve as a catalyst for fundamental business-structure reforms. - FY2022-Q2RestatedAnnual report
「Meanwhile, in the medical mask market following DS2 certification, obtaining the required US and European certifications (Note 1) is taking time. As overseas-made N95 masks remain overwhelmingly dominant, we will continue developing this market from a long-term perspective.」
The company continues to develop the medical mask market using DS2 certification as a foothold, premised on obtaining US and European certifications and pursuing long-term market development. - FY2022-Q1AdvancedAnnual report
「Regarding the mass-production system for masks, which is a challenge for the profitability of the business, the Company expects to achieve substantial cost reductions through production rationalization by introducing a fully automated line scheduled to begin operation in the second quarter. Since imported N95 masks are overwhelmingly dominant in the medical-use mask market following DS2 certification, the Company will pursue development of this market from a long-term perspective.」
The Company is pursuing development of the medical-use market following DS2 certification for its mask business and has presented cost-reduction measures using a fully automated line scheduled to begin operation in the second quarter. - FY2021-Q3AdvancedAnnual report
「Beginning in the second quarter, the Company gradually started selling the “Ultimate YAMASHIN Filter Mask” and “Ultimate YAMASHIN Filter Sheet,” using its proprietary synthetic polymer nanofiber technology, through its official online shop, major drugstore chains, major e-commerce sites and other channels. Leveraging technology cultivated over 70 years as a filter specialist since its founding, the Company also began selling “Zexeed” (ゼクシード) from November 2020, a flagship consumer model that achieves at a medical-use level the 3 key performance criteria required for high-performance masks: ① filtration performance, with a collection efficiency of at least 95% (Note 2), based on the performance standard for N95 masks (Note 1), one of the standards of NIOSH (the National Institute for Occupational Safety and Health); ② sealing performance, with a face-to-mask fit rate of at least 90% while worn (Note 2); and ③ breathability, including ease of breathing during extended wear.」
The healthcare business expanded sales of masks and filter sheets through multiple channels and began selling Zexeed in November 2020. In the third quarter, the healthcare business reported external sales of ¥694 million and an operating loss of ¥18 million, with weak performance attributed to supply delays and insufficient cost reductions. - FY2021-Q2First statedAnnual report
「The Company commercialized YAMASHIN original masks and replacement inner sheets using its proprietary synthetic polymer nanofiber technology, began selling them through its e-commerce site in May 2020, and gradually began sales through major drugstore chains and other channels in September of the same year. As a result, their importance to the performance of the Group increased, and the Company decided to disclose segment information under a new “Healthcare Business” segment in addition to the existing “Construction Equipment Filter Business” and “Air Filter Business” segments.」
The Company disclosed the healthcare business as a new reportable segment following the commercialization of masks and replacement inner sheets and the start of sales through e-commerce and drugstores. It also developed “Zexeed,” with a filtration efficiency of at least 95% and a fit rate of at least 90% based on the N95 performance standard, and presented plans for a pre-launch in October 2020 and nationwide sales in November.